A Glutamine antagonist-modulated tumor microenvironment unleashes enzalutamide’s immunotherapeutic effects
Jianpeng Yu(Duke University), Jiaoti Huang(Space Science Institute), Haipei Yao(Duke Medical Center), Xia Gao(China University of Petroleum, East China), J T Chen(Duke University), Daniel J. George(Duke University), Herman F. Staats(Duke University), Bangchen Wang(Duke University), David M. Ashley(Unknown), Michelle Bowie(Creative Research Enterprises (United States)), Hong Zhang(Central South University), YW He(Duke University), Xue Jiang(Duke University), Zichun Xing(Duke University), Robert Wild(Tracon Pharmaceuticals (United States)), Olivia Meng(Duke University), Fan Zhang(Duke University), Moyasar A. Alhamo(Duke University), Yi Zhang(Duke University), Christopher J. Pirozzi(Duke University)
Cited by 0
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Highly Efficient Capture of Circulating Tumor Cells by Using Nanostructured Silicon Substrates with Integrated Chaotic Micromixers
|Angewandte Chemie International Edition|2011|618
Longitudinal molecular trajectories of diffuse glioma in adults
|Nature|2019|594
Notch-Dependent Differentiation of Adult Airway Basal Stem Cells
|Cell stem cell|2011|480